Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.90 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.90 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.90 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.90 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.90 |
| ▸ | NSD2 | O96028 | 1/20 | 0.89 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.89 |
| ▸ | BID | P55957 | 1/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.89 |
| ▸ | ASPH | Q12797 | 1/20 | 0.89 |
| ▸ | BAD | Q92934 | 1/20 | 0.89 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.89 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1701509 | 1.00 | BCL2 (0.90) | BCL2BCL2L1MCL1BCL2L2TMEM97 | |
| SCHEMBL1702267 | 0.96 | BCL2 (0.90) | BCL2BCL2L1MCL1BCL2L2TMEM97 | |
| SCHEMBL1702263 | 0.96 | BCL2 (0.90) | BCL2BCL2L1MCL1BCL2L2TMEM97 | |
| SCHEMBL9971814 | 0.95 | BCL2 (0.92) | BCL2BCL2L1MCL1BCL2L2TMEM97 | |
| A-1211212 SCHEMBL1699818 | 0.94 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2TMEM97 | |
| SCHEMBL1699909 | 0.94 | BCL2 (0.91) | BCL2BCL2L1MCL1BCL2L2TMEM97 | |
| A-1211212 SCHEMBL523882 | 0.94 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2TMEM97 | |
| SCHEMBL1699906 | 0.94 | BCL2 (0.91) | BCL2BCL2L1MCL1BCL2L2TMEM97 | |
| A-1211212 SCHEMBL30313858 | 0.94 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2TMEM97 | |
| A-1211212 SCHEMBL30313959 | 0.94 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576546-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE BAHAMAS LTD (BS) | 2015-07-22 | — | — | EP | claimed |
| US-8580794-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-11-12 | — | — | US | claimed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | claimed |
| EP-2576546-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE BAHAMAS LTD (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-9034875-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8580794-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2576546-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.